

Exploring Diverse Protein Interactions using the Sengenics Protein Array

Technology background

Recombinant protein expression is a fundamental technique that underpins clinical diagnostics, drug discovery and screening, vaccine development and pure research for elucidating mechanisms of disease development and progression. However, high-throughput production of correctly folded and functional, full-length human proteins has a very high failure rate. Protein folding is a highly complex process requiring a combination of an aqueous environment, chaperones, post-translational modifications and the formation of multimeric structures held together by covalent bonds. Any deviation from the correct sequence of events can result in a misfolded protein. Loss of protein function is directly linked to misfolding. Use of misfolded proteins in downstream assays and interactions studies can result in identification of false positive biomarkers.

The Sengenics KREX™ technology utilises the biotin carboxyl carrier protein (BCCP) as a folding marker and solubility enhancer which results in high-throughput expression of full-length, correctly folded and functional proteins. BCCP-protein fusions are capable of being biotinylated either *in vivo* or *in vitro*, allowing the use of highly specific biotin-streptavidin interaction for surface capture. As biotinylated proteins bound to a streptavidin-coated surface show negligible dissociation, this interaction therefore provides a vastly superior means for tethering proteins to a planar surface and is ideal for applications such as protein microarrays, glass micro-titer plates, SPR and bead-based assays.




Figure 1. The BCCP folding marker acts as a marker for correctly folded proteins. Proteins will be immobilised on the array only when they are properly folded and biotinylated on the BCCP folding marker.

Introduction

Leveraging the KREX™ technology, we have developed a fully quantitative protein microarray platform which affords the simultaneous screening of over thousands of functional proteins for various medical and therapeutic proteomics applications. All arrayed proteins are assayed simultaneously under identical conditions resulting in quantitative and genuinely comparative data. It is a highly reproducible, miniaturised assay platform for systematic, high-throughput studies of protein function.

This platform allows us to elucidate the roles of various different proteins in the context of its interaction with other proteins, peptides, DNA, RNA and small molecules. Utilising the KREX™ technology ensures that all immobilised proteins to any purpose-designed solid support platforms (e.g. protein microarrays) are full-length, correctly folded and functional, with both linear and conformational epitopes captured, thus ensuring any interactions that take place are true interactions, and not due to non-specific attachment or binding of proteins which usually occurs with other high-throughput proteomics platforms.

TECHNICAL PERFORMANCE

- Expression of correctly folded and functional proteins with a 98% success rate.
- Fully quantitative clinical-grade assay metrics. Dynamic range is linear up to five orders of magnitude.
- Excellent reproducibility and precision with a mean CV% below 4% between replica arrays.
- Highly sensitive with a limit of detection of approximately 1:1,000,000 serum dilution and autoantibody titer of 190 pg/mL.
- Exceptional specificity and accuracy: non-specific binding eliminated as all proteins are immobilised as functional and correctly folded BCCP-fusions.




Figure 2. Protein interaction with different types of analytes. Hall, Ptacek & Snyder, 2007.

Case studies

1. NYO-ESO-1 vaccine interaction in Melanoma patients (Beeton-Kempen N. et. al., 2014)

Study Design:

- 46 melanoma patients, vaccinated with NY-ESO-1 repeatedly (D1, D28, D56, D140, D231).
- Inclusion criteria: Tumor expression of NY-ESO-1 antigen by immunohistochemistry.
- Serum samples taken at D0 and at 2 weeks after each vaccination event.
- 127 sera analysed on the Sengenics protein array platform covering a total of 123 tumor associated antigens (TAAs).

Results

As regulatory T cells can interfere with immune responses in patients with cancer, using a small dose of cyclophosphamide to suppress regulatory T cells increased patient responses to the NY-ESO-1 ISCOMATRIX® vaccine. This also increases the autoantibody titer,

indicating that autoantibodies can be used for monitoring treatment response in cancers.




Figure 3. Complete data for individual patients: In a few patients, many autoantibodies apparently increased in titer post-vaccination.

2. DNA-binding analysis using a p53 protein microarray (Boutell, J.M. et. al., 2004)

Study Design:

Protein-protein interactions between p53 variants and, i) a regulatory onco-protein, ii) a regulatory kinase resulting in on-chip phosphorylation

Mutation	DNA binding		MDM2	CKII
	B _{max} /% wild-type	K _d /nM		
Wild-type	100 (90–110)	7 (5–10)	+	+
W23A	131 (119–144)	7 (5–10)	–	+
W23G	84 (74–94)	5 (3–9)	–	+
R72P	121 (110–132)	9 (7–13)	+	+
P82L	70 (63–77)	7 (5–10)	+	+
M133T	ND		+	+
Q136X	No binding		+	–
C141Y	ND		+	+
P151S	ND		+	+

Figure 4. The binding affinity constant (K_d) and B_{max} value for some of the variants.

Results

Proteins with mutations outside of the DNA-binding domain generally had near wild-type affinity for DNA. By contrast, total loss of binding was observed for mutations resulting in truncated proteins and mutations that monomerise the protein.

Custom protein array development

Viral infections are mediated by several protein–protein interactions. Protein domains are basic units defining protein interactions and mutations at protein interfaces can reduce or increase their binding affinities by changing protein electrostatics and structural properties. During the course of a viral infection, both pathogen and cellular proteins are constantly competing for binding partners. Endogenous interfaces mediating intraspecific interactions—viral–viral or host–host interactions—are constantly targeted and inhibited by exogenous interfaces mediating viral–host interactions. Blocking such interactions is the main mechanism underlying antiviral therapies (Brito and Pinney, 2017). A protein array consisting of antigens from different bacterial/viral strains can be developed and used to evaluate human sera. The array will allow simultaneous examination of the magnitude of antibody responses, the isotype of such antibodies, and the breadth of the bacterial/viral strain recognition.

Current Study:

Protein X is a membrane protein (MP) of virus Z, key to the pathogenesis of infection, it is therefore important as a potential

vaccine candidate. The aim is to develop Protein X-based vaccine that can elicit serum antibodies capable of suppressing virulence.

Strategy:

Detect and evaluate Z membrane protein, protein X, as a vaccine component. Detect the MPs in which antibody response occur predominantly, and evaluate the MPs detected for their potential as vaccines.

Expected Results:

High efficacy vaccine candidate for virus Z infection.




Figure 4. A good vaccine candidate should be able to disrupt, block or inhibit an interaction that is involved in viral entry or attachment.

References

1. Beeton-Kempen N, Duarte J, Shoko A, Serufuri JM, John T, Cebon J, Blackburn J. Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. International journal of cancer. 2014;135:1842–1851.
2. Boutell, J.M., Darren, J.H., Godber, B.L., Kozlowski, R.Z. & Blackburn, J.B. (2004) Functional protein microarrays for parallel characterisation of p53 mutants. *Proteomics* 4, 1950-1958.
3. Brito AF and Pinney JW. 2017. Protein–Protein Interactions in Virus–Host Systems. *Front. Microbiol.* <https://doi.org/10.3389/fmicb.2017.01557>.
4. Hall DA, Ptacek J and Snyder M. 2007. Protein microarray technology. *Mech Ageing Dev.*; 128(1): 161–167.

Terms and conditions

Patented KREX functional proteomics technology which utilises the BCCP folding marker for the production of full-length, correctly folded and functional proteins. Protected by the following patents: EP1203238, JP4730804, GB2361698, US7816098, EP1470229, AU2003238441, US8999897, JP4377242, CA 2474457, EP1485411, CA2518927C, EP1456668, AU2002352355, JP4781628. Trademarked in the United Kingdom UK00003167383 under classes 05, 10 and 16. Except as otherwise agreed to by us in writing, the purchase of Products from us only conveys to you the non-transferable right for you to use the quantity of Products purchased in compliance with any applicable limited use statement or limited label license, as detailed in our catalogues, on our website, or on the label or other documentation accompanying the goods (all such statements or licenses being incorporated herein by reference as if set forth herein in their entirety). Unless otherwise authorized by us in writing, Products purchased from us may not be resold, modified for resale, or used to manufacture commercial products. All products and results from services are supplied / handed over by us to you on the condition that they may only be used by you alone (and no other third parties for and/or on your behalf) as instructed and directed in writing by Sengenics for your own internal, non-commercial and non-revenue and non-fee generating research purposes only. They are not in any circumstances to be used for drug or diagnostic purposes, nor are they intended for use in or on humans. By accepting delivery of our products or services, you are expressly agreeing to use our products or services for internal, non-commercial and non-revenue and non-fee generating research purposes only as specified in this paragraph. Products are not to be repackaged or resold and results from services are not to be used for any purpose apart from the research purposes specified in this paragraph. Any non-research use requires an ITAP license, the cost of such license is based upon the type of application of any Sengenics technologies, products or services for any purpose other than the internal, non-commercial and non-revenue and non-fee generating research purposes specified in this paragraph. You represent and warrant to us that the Products sold to you (i) will be used only for your own internal research, (ii) will only be used in compliance with any applicable limited use statement or limited label license or applicable law and (iii) will not be resold or otherwise transferred or conveyed to any third party. No license or immunity under any patent is either granted or implied by the sale of any of our Products except to the extent expressly granted in any respective label license or limited use statement (all such statements or licenses being incorporated herein by reference as if set forth herein in their entirety). You should evaluate whether your use of Products purchased from Sengenics requires permission or license from any third parties. Nothing in these Terms shall be deemed or construed (i) as a license or grant of any intellectual property, whether implied, by estoppel or otherwise except to the extent expressly granted under any applicable intended use statement, limited use statement or limited label license; (ii) to limit our rights to enforce our Intellectual Property, including, without limitation, as to use of any Product beyond that granted under any label license or statement applicable to the Products; (iii) as granting you any right to be supplied with goods or component thereof beyond those ordered by you and supplied by us in accordance with these Terms; or (iv) as a license or grant of any right to you to manufacture or to have manufactured the Products.

Full Sengenics Terms and Conditions are available from www.sengenics.com or upon request.

For general enquiries please email enquiries@sengenics.com

For technical support please email support@sengenics.com